Peptides CDMO AmbioPharm, has broken ground on a 650 m², $28 million expansion project at its Shanghai manufacturing site. This is due to be complete in 2H 2025 and will produce over 8 tonnes/year of crude peptide.

Building 2, as it is called will feature advanced fragment-based peptide synthesis with multiple 1,000-3,000L solid- and liquid-phase lines. The output will be further processed using existing downstream purification and isolation capabilities at the company’s sites in North Augusta, South Carolina, and Shanghai itself.